Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives

Leong, James, McAuslane, Neil, Walker, Stuart and Salek, Mir-saeed 2013. Is there a need for a universal benefit-risk assessment framework for medicines? Regulatory and industry perspectives. Pharmacoepidemiology and Drug Safety 22 (9) , pp. 1004-1012. 10.1002/pds.3464

Full text not available from this repository.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	benefit–risk assessment; framework; benefit–risk methodologies; pharmaceutical industry; regulatory agency; universal; pharmacoepidemiology
Additional Information:	An abstract was presented as a poster at the DIA 2012 48th Annual Meeting: DIA 2012 48th Annual Meeting Poster Abstracts. Drug Information Journal 2012; 46: 494–504. DOI:10.1177/0092861512449813.
Publisher:	John Wiley & Sons
ISSN:	1099-1557
Last Modified:	11 Feb 2022 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/56566

Citation Data

Cited 21 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item